Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
about
Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromesThrombopoietin receptor levels in tumor cell lines and primary tumorsEltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiationLow or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature.Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.Thrombopoiesis-stimulating agents and myelodysplastic syndromes.Eltrombopag for treatment of thrombocytopenia-associated disorders.Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.Thrombopoietin mimetics for patients with myelodysplastic syndromes.Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders.
P2860
Q26863182-019B69D4-EA38-4847-810A-EE16952E0C83Q33394117-3DA5012C-AFEA-41BF-89A4-F6150FF81D55Q33401421-A43A6DED-09AA-4BB9-8398-EC6238FD3225Q33403234-F27ABFC2-4903-4E71-806F-954C115A4AB6Q33411387-83A2C1ED-F2F6-42CD-AEA8-EDA4CD6C205AQ33412339-10C696A2-6BE7-4CAA-BB9D-AF29C7130C88Q33414087-F89AD920-C43A-4AD3-8EBD-16844B865BDBQ33420207-B8214B40-F037-4D7B-AC81-105C718D8557Q33425805-A47114F6-239C-4A58-8975-1FA7795759DEQ47125041-4F6D4DAF-65AF-4AAB-AE0D-18EF5B3B4E5AQ47550396-BE540227-7E2F-4795-919A-C9BFD21631D1Q48327578-072967C1-55FD-4A66-BB16-A3B0A8C0A3CC
P2860
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@ast
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@en
type
label
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@ast
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@en
prefLabel
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@ast
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@en
P2093
P1433
P1476
Effect of the nonpeptide throm ...... risk myelodysplastic syndrome.
@en
P2093
Androniki Kozana
Charalampos Pontikoglou
Christina Kalpadakis
Helen A Papadaki
Irene Mavroudi
Katerina Pyrovolaki
Konstantia Pavlaki
Maria Psyllaki
P304
P356
10.1016/J.LEUKRES.2010.06.029
P577
2010-08-04T00:00:00Z